DiaSorin S.p.A., headquartered in Italy, is a prominent player in the global diagnostics industry, specialising in the development and production of innovative diagnostic solutions. Founded in 1968, the company has established a strong presence in major operational regions, including Europe, North America, and Asia. With a focus on immunodiagnostics and molecular diagnostics, DiaSorin offers a range of unique products, including its LIAISON® and Simplexa™ platforms, which are renowned for their accuracy and efficiency. The company has achieved significant milestones, such as expanding its product portfolio and enhancing its technological capabilities, solidifying its market position as a leader in the field. Recognised for its commitment to quality and innovation, DiaSorin continues to advance healthcare diagnostics, making a meaningful impact on patient care worldwide.
How does Diasorin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Diasorin's score of 62 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, DiaSorin reported total carbon emissions of approximately 251,000 kg CO2e in Great Britain, with emissions distributed across various scopes: 80,000 kg CO2e from Scope 1, 16,000 kg CO2e from Scope 2, and 151,000 kg CO2e from Scope 3. Globally, their emissions were significantly higher, totalling about 251,000,000 kg CO2e, with Scope 1 emissions at 3,513,000 kg CO2e, Scope 2 emissions at 12,132,000 kg CO2e (market-based), and a substantial 226,256,000 kg CO2e from Scope 3. DiaSorin has set ambitious climate commitments, aiming for Net Zero emissions by 2050, with a near-term target to reduce emissions to 305,010 kg CO2e by 2028, representing an 18.52% reduction from current levels. These targets encompass all scopes of emissions and reflect the company's commitment to sustainability and climate action. The emissions data is sourced directly from DiaSorin S.p.A., with no cascaded data from parent or related organizations. The company continues to focus on reducing its carbon footprint while maintaining transparency in its reporting practices.
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 61,753,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 9,489.51 | 0,000.00 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - | 000,000,000 |
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Use of Sold Products" being the largest emissions source at 50% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Diasorin has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

